For its second fiscal quarter (ending June 30), Intra-Cellular Therapies Inc (NASDAQ: ITCI) has reported E.P.S. of $-0.16 compared to $-0.45 a year ago. This performance was $0.02 better than the consensus estimate of $-0.18. E.P.S. were $-0.86 for the latest four quarters through June 30 versus $-1.93 for the same period a year ago.
Recent Price Action
On 8/7/24, Intra-Cellular Therapies Inc (NASDAQ: ITCI) stock suffered a large decline of -5.8%, closing at $73.63. Moreover, unusually high trading volume at 166% of normal accompanied the decline. The stock has declined -5.7% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, ITCI is expected to continue to be Value Creation neutral.
Intra-Cellular Therapies has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Intra-Cellular Therapies has a very low Appreciation Score of 8 but a good Power Rating of 72, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment